Venus Remedies Balance Sheet Health
Financial Health criteria checks 6/6
Venus Remedies has a total shareholder equity of ₹4.9B and total debt of ₹413.3M, which brings its debt-to-equity ratio to 8.5%. Its total assets and total liabilities are ₹6.3B and ₹1.4B respectively. Venus Remedies's EBIT is ₹333.6M making its interest coverage ratio 370.7. It has cash and short-term investments of ₹871.9M.
Key information
8.5%
Debt to equity ratio
₹413.30m
Debt
| Interest coverage ratio | 370.7x |
| Cash | ₹871.90m |
| Equity | ₹4.88b |
| Total liabilities | ₹1.39b |
| Total assets | ₹6.27b |
Recent financial health updates
Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt
Jun 13
Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly
Jun 03Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
May 31Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
Feb 01We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt
Jan 14Is Venus Remedies (NSE:VENUSREM) A Risky Investment?
Sep 22Recent updates
Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%
Jun 14Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt
Jun 13Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%
Mar 14Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)
Oct 31Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly
Jun 03Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)
Jul 15Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
May 31I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease
Mar 30Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge
Feb 24Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
Feb 01Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching
Nov 16Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?
Mar 11We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt
Jan 14Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 23Is Venus Remedies (NSE:VENUSREM) A Risky Investment?
Sep 22Financial Position Analysis
Short Term Liabilities: VENUSREM's short term assets (₹3.6B) exceed its short term liabilities (₹794.2M).
Long Term Liabilities: VENUSREM's short term assets (₹3.6B) exceed its long term liabilities (₹598.6M).
Debt to Equity History and Analysis
Debt Level: VENUSREM has more cash than its total debt.
Reducing Debt: VENUSREM's debt to equity ratio has reduced from 89.6% to 8.5% over the past 5 years.
Debt Coverage: VENUSREM's debt is well covered by operating cash flow (90.2%).
Interest Coverage: VENUSREM's interest payments on its debt are well covered by EBIT (370.7x coverage).